Arcoma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Mattias Leire

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure1.8yrs
Board average tenure7.8yrs

Recent management updates

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Recent updates

Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Nov 09
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

Aug 22
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Aug 07
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26
Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06
Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Is Arcoma (STO:ARCOMA) A Risky Investment?

Jan 15
Is Arcoma (STO:ARCOMA) A Risky Investment?

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Sep 11
We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Jun 08
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Apr 27
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Dec 22
Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

May 03
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Oct 28
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Is Arcoma (STO:ARCOMA) A Risky Investment?

Mar 17
Is Arcoma (STO:ARCOMA) A Risky Investment?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Feb 04
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21
Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

CEO

Mattias Leire (43 yo)

1.8yrs

Tenure

Mr. Mattias Leire is Chief Executive Officer of Arcoma AB from February 2023. He joined the Arcoma AB in 2023. He has extensive experience from leading positions, including many years within Atos Medical....


Leadership Team

NamePositionTenureCompensationOwnership
Mattias Leire
Chief Executive Officer1.8yrsno datano data
Johan Dahlberg
Chief Financial Officer2.5yrsno datano data
Daniel Warawasowski
Global Sales Directorless than a yearno datano data

1.8yrs

Average Tenure

41yo

Average Age

Experienced Management: ARCOMA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jan Wahlstrom
Independent Director2.5yrsSEK 100.00kno data
Mats Thoren
Director14.8yrsSEK 100.00kno data
Lars Kvarnhem
Chairman7.8yrsSEK 400.00kno data

7.8yrs

Average Tenure

53yo

Average Age

Experienced Board: ARCOMA's board of directors are considered experienced (7.8 years average tenure).